Dr. Richard Christopherson

Biography

Richard Christopherson is an Emeritus Professor at the University of Sydney, specializing in the field of Life and Environmental Sciences. His research primarily focuses on proteomics and mass spectrometry, aiming to develop new methods for the classification of chronic lymphocytic leukemia (CLL) and to elucidate the mechanisms of action of drugs that are effective in treating this condition. A significant aspect of his work involves the use of 'small molecule' inhibitors such as Ibrutinib and Idelalisib, which have revolutionized the treatment landscape for CLL. He investigates how these kinase inhibitors alter protein phosphorylation patterns in CLL cells, helping to understand the signaling pathways that drive cellular proliferation. Richard has collaborated extensively with other researchers, including those from prestigious institutions like the University of North Carolina, focusing on the identification of proteins and understanding their phosphorylation changes, particularly in the context of treatment with 2-FaraA. Additionally, he is involved in developing engineered antibodies for conditional bispecific T cell engagers (cBITE) to treat CLL, working alongside researchers from Monash University. His contributions to the field are supported by numerous grants and collaborations, enabling advancements in cancer biochemistry and translational research across various malignancies and emphasizing the importance of proteomics in these efforts.

Research Interests